GlaxoSmithKline is assessing its global research and development facilities, which could lead to some of its less established centres closing.
It has more than half a dozen facilities in the UK and the US.
It wants to concentrate research around six centres of excellence.
Financial Times 28/05/01 page 19
The independent adjudicator is free to move from Midtown after change of use approved
COMMENT Ed Mayes on a chance to back brownfield, boost housing delivery and champion partnership
The Acton site has consent for 429 student rooms and 95 affordable homes
The company’s international production arm will move in before the 2026/2027 season kicks off
